focus -WSS

focus

author：entertainment 2025-09-27 13:10:57 - browse：847

PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

“We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

WSS

Kidney transplant patients stopped immunosuppressants in trial

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Coloradans with cystic fibrosis could lose access to Trikafta

Orchard's therapy for neuron disease in children wins FDA approval

DeepMind touts AlphaFold's new skills as protein folding AI models face off

leisure time

focus

focus

Continuity nursing helped my family in our darkest PICU moments

Gene therapy’s promise and the high cost of hope

How to save PrEP access — and even expand it

How to convince healthy people to buy insurance

Hollywood unions extend contract negotiations for actors

Readout LOUD podcast: ESMO highlights & Roivant's big deal

The cancer drug shortage isn’t new — and neither are the solutions

Infant mortality in U.S. rose last year for first time in decades: CDC

How to save PrEP access — and even expand it

Future doctors should be trained to promote social change

explore

SCOTUS questions limit to govt efforts to fight misinformation

U.K. researchers warn about biases in medical devices, algorithms

U.K. researchers warn about biases in medical devices, algorithms

Key Senate panel to consider PBM, drug pricing reform package

Neuroscience’s long legacy of racism

App could help diagnose ear infections more accurately — and at home

entertainment

hotspot

leisure time

hotspot